Building the Group for future growth
Business Update Oxford, UK – 18 March 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today an unaudited trading and…
Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this…
Interim results for the six months ended 30 June 2019
Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six…
Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease
June 26, 2019, Oxford, UK and Osaka Japan–Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic…
Exercise of Subscription Option by Novo Holdings
Oxford, UK – 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to…
Oxford Biomedica announces strategic investment by Novo Holdings A/S
Oxford, UK – 28 May 2019: Oxford Biomedica plc (LSE:OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has…
Oxford Biomedica to present at the Annual Meeting of the American Society of Gene & Cell Therapy
Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral…
Oxford Biomedica notes that Axovant has announced the dosing of the first patient in the second cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD
– Under terms of the agreement with Axovant signed in June 2018, this has triggered a $15 million milestone to Oxford Biomedica Oxford, UK – 30 April 2019: Oxford Biomedica…
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis that Japan’s Ministry of Health, Labor and…
Oxford Biomedica plc preliminary results for the year ended 31 December 2018
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy…
Oxford Biomedica plc preliminary results for the year ended 31 December 2018
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy…
Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning
Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with…